Garden State Investment Advisory Services LLC Takes $2.12 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Garden State Investment Advisory Services LLC purchased a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 16,936 shares of the biotechnology company’s stock, valued at approximately $2,115,000.

Other large investors have also bought and sold shares of the company. Innealta Capital LLC acquired a new stake in Sarepta Therapeutics during the 2nd quarter worth $31,000. Huntington National Bank lifted its stake in shares of Sarepta Therapeutics by 150.9% in the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 175 shares during the period. Nkcfo LLC bought a new position in shares of Sarepta Therapeutics in the 2nd quarter worth $43,000. Riggs Asset Managment Co. Inc. grew its stake in shares of Sarepta Therapeutics by 33.3% during the second quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 75 shares during the period. Finally, UMB Bank n.a. increased its holdings in Sarepta Therapeutics by 105.9% in the third quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 197 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on SRPT shares. Royal Bank of Canada restated an “outperform” rating and set a $182.00 target price on shares of Sarepta Therapeutics in a report on Monday, October 21st. UBS Group lifted their price objective on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. Guggenheim upped their target price on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $152.00 to $167.00 in a report on Thursday, November 7th. Finally, Robert W. Baird decreased their price target on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. One research analyst has rated the stock with a sell rating, two have given a hold rating, twenty have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $175.77.

Sarepta Therapeutics Price Performance

NASDAQ:SRPT opened at $132.00 on Monday. The stock’s 50-day simple moving average is $122.50 and its 200 day simple moving average is $131.48. Sarepta Therapeutics, Inc. has a 52-week low of $83.97 and a 52-week high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The company has a market cap of $12.61 billion, a P/E ratio of 106.67 and a beta of 0.81.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.